Verastem directors buy $475K of stock, company set for potential pivotal trials

Three directors of cancer drug company Verastem Inc. and its founding executive chairman have purchased $475,000 worth of the company’s stock in the past week as it plans to start a potential pivotal trial against mesothelioma in coming months...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.